CAR T-cell therapy: Toxicity and the relevance of preclinical models

Immunotherapy

Volumn 7, Issue 5, 2015, Pages 487-497

  Kalaitsidou, Milena ^a   Kueberuwa, Gray ^a   Schütt, Antje ^a   Gilham, David Edward ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

adoptive cell therapy; CAR T cells; cytokine storm; preclinical models; toxicity

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CELL FUNCTION; CELL THERAPY; CELLS BY BODY ANATOMY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; GENOTOXICITY; HUMAN; IMMUNOTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; IMMUNOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; CYTOKINES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84931031622     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.123     Document Type: Review

References (64)

1. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin- T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86(24), 10024-10028 (1989).
2. Kahlon KS, Brown C, Cooper LJN, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64(24), 9160-9166 (2004).
3. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)- engineered lymphocytes for cancer therapy. Expert Opin. Biol. Ther. 11(7), 855-873 (2011).
4. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE. Building better chimeric antigen receptors for adoptive T cell therapy. Curr. Gene Ther. 10(2), 77-90 (2010).
5. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257(1), 107-126 (2014).
6. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol. Rev. 257(1), 127-144 (2014).
7. June CH, Maus MV, Plesa G et al. Engineered T cells for cancer therapy. Cancer Immunol. Immunother. 63(9), 969-975 (2014).
8. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17), 2625-2635 (2014).
9. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 29(11), 550-557 (2011).
10. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3(4), 388-398 (2013).
11. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257(1), 83-90 (2014).
12. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol. Immunother. 61(7), 953-962 (2012).
13. Vonderheide RH, June CH. Engineering T cells for cancer: our synthetic future. Immunol. Rev. 257(1), 7-13 (2014).
14. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 20(2), 119-122 (2014).
15. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra225 (2014).
16. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12), 2709-2720 (2012).
17. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116(20), 4099-4102 (2010).
18. Cheadle EJ, Gilham DE, Hawkins RE. The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br. J. Haematol. 142(1), 65-68 (2008).
19. Hillerdal V, Ramachandran M, Leja J, Essand M. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer 14, 30 (2014).
20. Parente-Pereira AC, Burnet J, Ellison D et al. Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice. J. Clin. Immunol. 31(4), 710-718 (2011).
21. Zhao Y, Moon E, Carpenito C et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70(22), 9053-9061 (2010).
22. Alcantar-Orozco EM, Gornall H, Baldan V, Hawkins RE, Gilham DE. Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum. Gene Ther. Methods 24(5), 310-320 (2013).
23. Hannon M, Lechanteur C, Lucas S et al. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion 54(2), 353-363 (2014).
24. Zhou Q, Facciponte J, Jin M, Shen Q, Lin Q. Humanized NOD-SCID IL2rg-/- mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett. 344(1), 13-19 (2014).
25. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra225 (2014).
26. Wilkinson RW, Ross EL, Ellison D, Zimmermann W, Snary D, Mather SJ. Evaluation of a Transgenic Mouse Model for Anti-Human CEA Radioimmunotherapeutics. J. Nucl. Med. 43(10), 1368-1376 (2002).
27. Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev. Clin. Immunol. 5(5), 499-521 (2009).
28. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N. Engl. J. Med. 364(19), 1844-1854 (2011).
29. Cheadle EJ, Hawkins RE, Batha H, ONeill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J. Immunol. 184(4), 1885-1896 (2010).
30. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177), 177ra38 (2013).
31. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843-851 (2010).
32. Coffman KT, Hu M, Carles-Kinch K et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 63(22), 7907-7912 (2003).
33. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
34. Gan HK, Burgess AW, Clayton AHA, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 72(12), 2924-2930 (2012).
35. Maher J, Wilkie S. CAR mechanics: driving T cells into the MUC of cancer. Cancer Res. 69(11), 4559-4562 (2009).
36. Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: Review of an immunogenic tumor antigen. Adv. Cancer Res.95,1-30 (2006).
37. Sang M, Lian Y, Zhou X, Shan B. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine 29(47), 8496-8500 (2011).
38. Tsai J-R, Chong I-W, Chen Y-H et al. Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer 56(2), 185-192 (2007).
39. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 10(5), 267-276 (2013).
40. Till BG, Jensen MC, Wang J et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains. pilot clinical trial results. Blood 119(17), 3940-3950 (2012).
41. Cheadle EJ, Sheard V, Rothwell DG et al. Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19- specific second-generation chimeric antigen receptor T cells in a mouse model. J. Immunol. 192(8), 3654-3665 (2014).
42. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2- associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644), 415-419 (2003).
43. Scholler J, Brady TL, Binder-Scholl G et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 4(132), 132ra153 (2012).
44. Wang LX, Westwood JA, Moeller M et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res 70(23), 9591-9598 (2010).
45. John LB, Devaud C, Duong CP et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19(20), 5636-5646 (2013).
46. Muruganandan S, Sinal CJ. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin. Pharmacol. Ther. 83(6), 818-828 (2008).
47. Davies DM, Foster J, Van Der Stegen SJ et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol. Med. 18, 565-576 (2012).
48. Van Der Stegen SJC, Davies DM, Wilkie S et al. Preclinical In vivo Modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? J. Immunol. 191(9), 4589-4598 (2013).
49. Van Schalkwyk MC, Papa SE, Jeannon JP, Guerrero Urbano T, Spicer JF, Maher J. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T cells in locally advanced or recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 24(3), 134-142 (2013).
50. Kakarla S, Chow KKH, Mata M et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol. Ther. 21(8), 1611-1620 (2013).
51. Schuberth PC, Hagedorn C, Jensen SM et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 11, 187 (2013).
52. Tran E, Chinnasamy D, Yu Z et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210(6), 1125-1135 (2013).
53. Wang LC, Lo A, Scholler J et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2(2), 154-166 (2014).
54. Marin V, Cribioli E, Philip B et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum. Gene Ther. Methods 23(6), 376-386 (2012).
55. Di Stasi A, Tey S-K, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673-1683 (2011).
56. Alonso-Camino V, Sanchez-Martin D, Compte M et al. CARbodies: human antibodies against cell surface tumor antigens selected from repertoires displayed on T cell chimeric antigen receptors. Mol. Ther. Nucleic Acids 2, e93 (2013).
57. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol. Hum. Gene Ther. Methods 24(6), 381-391 (2013).
58. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31(1), 71-75 (2013).
59. Grada Z, Hegde M, Byrd T et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105 (2013).
60. Fedorov VD, Themeli M, Sadelain M. PD-1-and CTLA- 4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy Responses. Sci. Transl. Med. 5(215), 215ra172 (2013).
61. Barrett DM, Zhao Y, Liu X et al. Treatment of Advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 22(12), 1575-1586 (2011).
62. Singh N, Liu X, Hulitt J et al. Nature of tumor control by permanently and transiently-modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol. Res. 2(11), 1059-1070 (2014).
63. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12(10), 671-684 (2012).
64. Xu Y, Zhang M, Ramos CA et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15. Blood 123(24), 3750-3759 (2014).